Top

Published in:

01-04-2019 | Letter to the Editor

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

Authors: Kenichi Makishima, Naoshi Obara, Kantaro Ishitsuka, Shinichiro Sukegawa, Sakurako Suma, Yusuke Kiyoki, Naoko Baba, Tatsuhiro Sakamoto, Takayasu Kato, Manabu Kusakabe, Hidekazu Nishikii, Naoki Kurita, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Yuichi Hasegawa, Shigeru Chiba

Published in: Annals of Hematology | Issue 4/2019

Excerpt

Dear Editor, …

Berentsen S, Tjønnfjord GE (2012) Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 26:107–115. https://doi.org/10.1016/j.blre.2012.01.002 CrossRefPubMed

Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, Sørbø JH, Tjønnfjord GE (2006) Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 91:460–466PubMed

Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, Galteland E, Haukås E, Brudevold R, Sørbø JH, Næss IA, Malecka A, Tjønnfjord GE (2017) Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood 130:537–541. https://doi.org/10.1182/blood-2017-04-778175 CrossRefPubMed

Wong EK, Kavanagh D (2015) Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 165:306–320. https://doi.org/10.1016/j.trsl.2014.10.010 CrossRefPubMed

Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE et al (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552–559. https://doi.org/10.1056/NEJMoa031688 CrossRefPubMed

Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P et al (2006) The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 355:1233–1243. https://doi.org/10.1056/NEJMoa061648 CrossRefPubMed

Shapiro R, Chin-Yee I, Lam S (2015) Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. Clin Case Rep 3:942–944. https://doi.org/10.1002/ccr3.399 CrossRefPubMedPubMedCentral

Roth A, Hüttmann A, Rother RP, Dührsen U, Philipp T (2009) Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 113:3885–3886. https://doi.org/10.1182/blood-2009-01-196329 CrossRefPubMed

Gupta N, Wang ES (2014) Long-term response of refractory primary cold aggulutinin disease to eculizumab therapy. Ann Hematol 93:343–344. https://doi.org/10.1007/s00277-013-1800-7 CrossRefPubMed

Title: High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease
Authors: Kenichi Makishima
Naoshi Obara
Kantaro Ishitsuka
Shinichiro Sukegawa
Sakurako Suma
Yusuke Kiyoki
Naoko Baba
Tatsuhiro Sakamoto
Takayasu Kato
Manabu Kusakabe
Hidekazu Nishikii
Naoki Kurita
Yasuhisa Yokoyama
Mamiko Sakata-Yanagimoto
Yuichi Hasegawa
Shigeru Chiba
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 4/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3521-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

Allogeneic hematopoietic stem cells transplantation improves the survival of intermediate-risk acute myeloid leukemia patients aged less than 60 years

Vascular density and inflammatory infiltrate in primary oral squamous cell carcinoma and after allogeneic hematopoietic stem cell transplantation

Deciphering the prognostic significance of autoimmune disorders in myelodysplastic syndromes

An under-recognized cause of copper deficiency mimicking myelodysplastic syndrome

Low-dose splenic irradiation is an alternative therapy for symptomatic splenomegaly in patients with myelofibrosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page